跳至主要内容
临床试验/NCT03062917
NCT03062917已完成不适用

Validation of Nasal and Bronchial Absorption Sampling Methods for the Assessment of RSV Bronchiolitis in Babies and Children

Imperial College Healthcare NHS Trust1 个研究点 分布在 1 个国家目标入组 152 人开始时间: 2015年10月2日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
152
试验地点
1
主要终点
Accuracy of Nasosorption for Viral Load Measurement

研究概览

简要总结

This study will compare the novel methods of NS and BS with the standard technique of nasophayngeal aspiration (NPA) and routine ETT suction. We shall assess the samples for diagnosis of RSV, viral load and immune responses in the airways of babies with RSV infection. We shall also assess the genetics of babies included in this study, to see if they may be vulnerable to RSV infection.

详细描述

In conjunction with a specialist medical device manufacturing company (Hunt Developments (Midhurst, West Sussex) we have produced novel nasosorption and bronchosorption kits that have CE marking. Both nasosorption and bronchosorption methods use synthetic absorptive matrix (SAM) strips: that look and feel like blotting paper, and will be placed onto the mucosal surface. These are comfortable to use and can be used at frequent intervals over extended periods of time. This non-invasive technique is ideal for infants and children, and it is possible to obtain neat mucosal lining fluid (MLF) even from normal healthy noses. The eluates contain cytokines and chemokines at high detectable levels on multiplex immunoassay.

We would like to use these SAMs to take MLF samples from the nasal and bronchial mucosal surfaces to see if these novel techniques can overcome the problems with current sampling methods. We plan to use these absorption techniques to measure RSV viral load. We also aim to look at the immune response in terms of the anti-viral interferon response (IFN-γ, IFN-λ, IFN-α2a, IP10, ITAC). In therapeutic studies in the future, it may be possible to document levels of drug (pharmacokinetics) in nasal MLF.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
2 Weeks 至 2 Years(Child)
性别
All
接受健康志愿者
是

入选标准

  • •Group 1 and Group 2
  • •Inclusion Criteria
  • •Infants aged 2 weeks-24 months
  • •Presentation to the Emergency Department with any upper respiratory tract infection (URTI) in the RSV season (Oct-March).
  • •OR • Documented RSV infection, admitted to the paediatric wards at St Mary's Hospital.

排除标准

  • •Any local or systemic factor that would influence the safety of nasal sampling.
  • •Bilateral indwelling nasal catheters or local nasal pathology preventing access for nasal sampling.
  • •Bleeding disorders.
  • •The baby is taking part in another interventional study.
  • •The parents or guardians not able to sign the informed consent from due to limited English or comprehension despite the use of independent interpreter services.
  • •Limited life expectancy of the baby,
  • •Inclusion criteria
  • •Hospitalised Infants admitted to the PICU at St. Mary's Hospital, aged 2 weeks-24 months with documented RSV infection (by rapid test and/or PCR).
  • •Infants of weight >2kg.
  • •On a conventional ventilator with an Endotracheal Tube (ETT) of >3.0mmm diameter
  • •Exclusion criteria
  • •Any local or systemic factor that would influence the safety of nasal sampling.
  • •Bilateral nasal catheters or local nasal pathology preventing access for nasal sampling.
  • •The baby is taking part in another interventional study.
  • •Prematurity - corrected gestational age <36 weeks, weight <2kg
  • •Significant hypoxia or instability precluding ventilator disconnection
  • •ETT < 3mm internal diameter
  • •Transcutaneous oxygen saturation of <95% on 60% oxygen
  • •Risk of bleeding
  • •Pneumothorax
  • •Infants receiving oral corticosteroid therapy at any time in past month
  • •Parents or guardians not able to sign informed consent from due to limited English or understanding despite the use of independent interpreter services.
  • •Limited life expectancy or a decision to limit management,
  • •Control Group 1 Inclusion criteria
  • •Babies, aged 2 weeks-24 months, attending routine outpatient appointments or undergoing elective surgical procedures.
  • •Exclusion criteria
  • •Any respiratory symptoms
  • •All other exclusion are the same as Groups 1 and 2
  • •Control Group 2
  • •Inclusion criteria
  • •Infants aged 2 weeks-24 months.
  • •Infants ventilated on the PICU for any condition
  • •Confirmed RSV negative by PCR of respiratory tract samples
  • •Exclusion Criteria
  • •All exclusions are the same as Group 3
  • •In addition - any concern about raised intracranial pressure

研究组 & 干预措施

Emergency Department

Other

Babies with suspected respiratory tract infection (RTI) in the ED

干预措施: Nasal and Bronchial Sampling (Diagnostic Test)

Paediatric Wards

Other

Babies with diagnosed RSV infection admitted to paediatric wards

干预措施: Nasal and Bronchial Sampling (Diagnostic Test)

Paediatric Intensive Care

Other

Babies with diagnosed severe RSV infection in PICU requiring mechanical ventilation

干预措施: Nasal and Bronchial Sampling (Diagnostic Test)

Health Controls

Other

Babies without respiratory symptoms, attending routine outpatient appointments or undergoing elective surgical procedures

干预措施: Nasal and Bronchial Sampling (Diagnostic Test)

Controls in Paediatric Intensive Care

Other

Babies without RSV infection but requiring mechanical ventilation in PICU

干预措施: Nasal and Bronchial Sampling (Diagnostic Test)

结局指标

主要结局

Accuracy of Nasosorption for Viral Load Measurement

时间窗: Throughout symptomatic respiratory infection, up to 1 month

To determine the difference in accuracy of nasosorption compared to NPA by assessment of level of viral load (measured by qPCR).

Accuracy of Bronchosorption for Viral Load Measurement, Compared to Tracheal Aspirate

时间窗: Throughout symptomatic respiratory infection, up to 1 month

To determine the difference in accuracy of bronchosorption (BSAM) compared to tracheal aspirate (TA) by assessment of level of viral load (measured by qPCR).

The Number of Sampling Visits on Which Participants Are Willing to Undergo Nasosorption and/or NPA Sampling

时间窗: Throughout symptomatic respiratory infection, up to 1 month

To determine the difference in tolerability of nasosorption compared to NPA by assessment of acceptance by infants and families. Samples were collected from participants up to twice daily throughout study involvement, as such each participant could have \>1 sampling visits.

次要结局

  • Immune Response(Throughout symptomatic respiratory infection, up to 1 month)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验